References
- Leppik IE. Role of new and established antiepileptic drugs. Epilepsia 39 (Suppl. 5), 2–6 (1998)
- Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an anti-epileptic drug: how close does levetiracetam come? Epileptic. Disold 5 (Suppl. 1), S17—S26 (2003).
- Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disond 2, 99–105 (2000).
- Brown P, Steiger MJ, Thompson PD eta]. Effectiveness of piracetam in cortical myoclonus. May. Disold 8, 63–68 (1993).
- Leppik IE. The place of levetiracetam in the treatment of epilepsy. Epilepsia 42\(Suppl. 4), 44–45 (2001).
- Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 40,1471–1483 (1999).
- Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG. Levetiracetam does not modulate neuronal voltage-gated Na + and T-type Ca2+ currents. Seizure 10,279–286 (2001).
- Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neumphalmacology 42, 346–352 (2002).
- Klitgaard H, Matagne A, Gobert J, Willfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur Phalmacol 353, 191–206 (1998).
- ••Primary research article which outlinesearly results from preclinical studies using levetiracetam in rodent models of seizure and epilepsy. These results suggest that the activity of levetiracetam differs from that of most other newer and older antiepileptic drugs and that levetiracetam may offer broad-spectrum efficacy.
- Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett. 306, 5–8 (2001).
- Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43, 9–18 (2002).
- Rigo J-M, Hans G, Nguyen L eta! The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. BE j Pharmacol 136, 659–672 (2002).
- Madeja M, Margineanu DG, Klitgaard H. Effect of levetiracetam on voltage-gated potassium channels: a novel antiepileptic mechanism of action? Epilepsia 42 (Suppl. 2), 19 (2001).
- Bischoff U, Schlobohm I. Levetiracetam had no effect on voltage-gated potassiumcudents in cultuird mouse hippocampal neurons. Poster presented at the Fifth Eumpean Congress of Epileptology October 6, Madrid, Spain (2002).
- Noyer M, Gillard M, Matagne A, Hénichart J-P, Willfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur j Pharmacol 286, 137–146 (1995).
- Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. Pharmacol 232,147–158 (1993).
- Löscher W, Hönack D, Rundfeldt C Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. I Phannacol Exp. Ther 284, 474–479 (1998).
- Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischaemia. Seizure 10,287–293 (2001).
- Gower AJ, Noyer M, Verloes R, Gobert J, Willfert E. ucb L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur. j Phannacol 222, 193–203 (1992).
- Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 22,207–213 (1995).
- Klitgaard HV, Matagne AC, Vanneste-Goemaere J, Margineanu DG. Effects of prolonged administration of levetiracetam on pilocarpine-induced epileptogenesis in rat. Epilepsia 42\(Suppl. 7), 114 (2001).
- Wasterlain CG, Mazarati AM, Klitgaard HV, Baldwin RA. Levetiracetam in experimental status epilepticus. Epilepsia 42\(Suppl. 7), 87 (2001).
- Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find. Exp. Clin. Pharmacol 25,123–129 (2003).
- Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85,77-85 (2000). Reviews results of pharrnacokinetic studies conducted in healthy volunteers, epilepsy patients and special populations. It highlights that levetiracetam has linear pharmacokinetics, is almost completely absorbed, has minimal protein binding, and has few pharmacokinetic drug interactions.
- Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 42\(Suppl. 4), 24–27 (2001).
- Kasteleijn-Nolst Trenité DGA, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. 25,225-230 (1996).
- Tong X, Patsalos PN. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in the rat brain. BE J. Phannacol 133, 867–874 (2001).
- Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology55,236–242 (2000).
- Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P for the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41,1179–1186 (2000).
- Ben-Menachem E, Falter U for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/din patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. 43i/Tsia 41, 1276–1283 (2000).
- Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 42 (Suppl. 4), 31–35 (2001). Reviews key efficacy data from the three pivotal Phase III trials conducted to evaluate levetiracetam therapy for the treatment of partial-onset seizures in adults. It describes the methodology, results, and conclusions of these well-controlled trials individually and highlights important pooled results.
- Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res. 42, 89–95 (2000).
- Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day-1 in adult patients with refractory epilepsy. Seizure 12,141–149 (2003).
- Morrell MJ, Leppik IE, French J, Ferrendelli J, Han J, Magnus L. The KEEPER' trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 54,153–161 (2003).
- Olwen GO. The SKATE study: interim analysis. Int. I Clin. Ffact. 57,544–545 (2003).
- Ben-Menachem E, Edrich P, Van Vleymen B, Sander JWAS, Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. 53,57–64 (2003).
- Krakow K, Walker M, Otoul C, Sander JWAS. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neumlogy56,1772–1774 (2001).
- Betts T, Yarrow H, Greenhill L, Barrett M. Clinical experience of marketed Levetiracetam in an epilepsy clinic — a one year follow-up study. Seizure 12, 136–140 (2003).
- Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12,131–135 (2003).
- Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9,80–87 (2000).
- Keppra® (levetiracetam) tablets. In: Physician's Desk Referenced 57th Edition. Thompson PDR, NJ, USA, 3221–3224 (2003).
- Harden C. Safety profile of levetiracetam. Epilepsia 42 (Suppl. 4), 36–39 (2001). Reviews key safety data from the three pivotal Phase III trials and a fourth supportive Phase III trial conducted to evaluate levetiracetam therapy for the treatment of partial-onset seizures in adults. The focus of the article is on adverse events; however, information on pregnancy and teratogenesis, sudden unexpected death in epilepsy (SUDEP), and overdosage is also reported.
- Cramer JA, De Rue K, Devinsky 0,Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 4,124–134 (2003).
- Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiracetam therapy. Neumlogy61, 704–706 (2003).
- Kramer G, Hösli I, Glanzmann R, Holzgreve W Levetiracetam accumulation in human breast milk. Epilepsia 43 (Suppl. 7), 105 (2002).
- Nicolas J-M, Collart P, Germ n B eta! In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug- Metab. Divas. 27, 250–254 (1999).
- Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53,47–56 (2003).
- Ragueneau-Majlessi I, Levy RII, Janik Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43,697–702 (2002).
- Levy RII, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 46,93–99 (2001).
- Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 47, 55–63 (2001).
- Cramer JA, Arrigo C, Van Hamm& G, Gauer LJ, Cereghino JJ for the N132 Study Group. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 41, 868–874 (2000).
- Cramer JA, Van Hamm& G and the N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 4,118–123 (2003).
- Pellock JM, Glauser TA, Bebin EM eta! Pharmacokinetic study of levetiracetam in children. Epilepsia 42,1574–1579 (2001).
- Glauser TA, Pellock JM, Bebin EM etal. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43,518–524 (2002).
- Wheless JW, Ng Y-T Levetiracetam in refractory pediatric epilepsy. J. Child Neural 17,413–415 (2002).
- Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur. Pediatr Neural 7,123–128 (2003)
- Kossoff EH, Bergey GK, Freeman JM, Vining EPG. Levetiracetam psychosis in children with epilepsy. Epilepsia 42, 1611–1613 (2001).
- Estrada G, Wildrick D, Pranzatelli M. Neuropsychiatric complications of levetiracetam in children with epilepsy. Epilepsia 43\(Suppl. 7), 56–57 (2002).
- Gustafson MC, Ritter FJ, Frost MD, Karney V, Hoskin C. Behavioral and emotional effects of levetiracetam in children with intractable epilepsy. Epilepsia 43\(Suppl. 7), 58–59 (2002).
- Kugler SL, Patel IM, Mandelbaum DE eta! Behavioral profile of levetiracetam inchildren. Epilepsia 43\(Suppl. 7), 59 (2002).
- de los Reyes EC, Sharp GB, Hale SE. Levetiracetam in the treatment of Lennox—Gastaut syndrome. Ann Neural 50\(Suppl. 1), S108 (2001).
- Barron TF, Faircloth VC, Yuncker LA eta! Levetiracetam adjunct therapy for refractory pediatric generalized epilepsies. Epilepsia 42\(Suppl. 7), 53 (2001).
- Bourgeois BFD, Holder DL, Valencia I et al Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. 441Epsia42\(Suppl. 7), 53–54 (2001).
- Mandelbaum DE, Kugler SL, Wenger EC eta! Clinical experience with levetiracetam and zonisamide in children with uncontrolled epilepsy. Epilepsia 42 (Suppl. 7), 182 (2001).
- Gustafson MC, Ritter FJ, Frost MD eta! Clinical experience with levetiracetam treating refractory, symptomatic seizures in children. Epilepsia 42 (Suppl. 7), 55 (2001).
- Hovinga C, Morris H, Holland K eta! Levetiracetam efficacy in adults and children. Epilepsia 42 (Suppl. 7), 213 (2001).
- Strunc MJ, Levisohm PM. Tolerability and efficacy of levetiracetam in children. Epilepsia 42 (Suppl. 7), 92 (2001).
- Websites
Websites
- Drug approvals for November 1999. Keppra (levetiracetam). FDA Center for Drug Evaluation and Research website. www.fda.govicderidaida1199.htm (Accessed August 15,2003).
- AED Pregnancy Registry. www.aedpregnancyregistry.org (Accessed August 18,2003).
- FDA approval letter for levetiracetam oral solution. www.fda/govicderifoilappletter/2003/ 215051tr.pdf (Accessed August 19,2003).